Table 1.
Characteristics of the study cohort by sample type
| Stool (n = 39) | Rectal swab (n = 39) | |
|---|---|---|
| Age (mean±SD) | 58.1 ± 10.4 | 57.7 ± 10.7 |
| Gender (% female) | 38.5 | 43.6 |
| Race (% Caucasian) | 76.9 | 74.4 |
| CPS (mean±SD) | 7.90 ± 1.29 | 7.62 ± 1.2 |
| MELD (mean±SD) | 15.87 ± 6.31 | 14.74 ± 5.08 |
| Cirrhosis etiology (%) | ||
| EtOH | 41 | 41 |
| NASH | 25.6 | 23.1 |
| HCV | 15.4 | 17.9 |
| PBC/PSC | 7.7 | 7.7 |
| Granulomatous | 0 | 2.6 |
| Multifactorial | 10.3 | 7.7 |
| Cirrhosis complications (%) | ||
| HE | 61.5 | 64.1 |
| Ascites | 92.3 | 94.9 |
| SBP | 5.1 | 5.1 |
| Varices | 43.6 | 48.7 |
| HCC | 2.6 | 2.6 |
| Medications (%) | ||
| Any antibiotic | 53.8 | 59.0 |
| Rifaximin | 41 | 48.7 |
| Lactulose | 51.3 | 53.8 |
| PPI | 41 | 46.2 |
Abbreviations: CPS, Child-Pugh Score; MELD, Model for End-Stage Liver Disease; EtOH, ethanol; NASH, nonalcoholic steatohepatitis; HCV, hepatitis C virus; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; HE, hepatic encephalopathy; SBP, spontaneous bacterial peritonitis; HCC, hepatocellular carcinoma; PPI, proton pump inhibitor.